Correction of Psoriatic T Cell Signatures by Deucravacitinib

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05858645
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • deucravacitinib — DRUG
    Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Study Details

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Key Dates

Start date
Oct 1, 2023
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: deucravacitinib treatment
    treatment with deucravacitinib for 6 months

Primary Outcome Measure

Change in Psoriasis Area and Severity Index (PASI) score [ Time Frame: pre-treatment, 4 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94115
Ray Cho, MD, PhD
[email protected]
415-575-0524

Find similar trials in San Francisco, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies